Phreesia (NYSE:PHR) Third Quarter 2025 Results
Key Financial Results
- Revenue: US$106.8m (up 17% from 3Q 2024).
- Net loss: US$14.4m (loss narrowed by 55% from 3Q 2024).
- US$0.25 loss per share (improved from US$0.58 loss in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Phreesia EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Healthcare Services industry in the US.
Performance of the American Healthcare Services industry.
The company's shares are up 16% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Phreesia you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:PHR
Phreesia
Provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.
Very undervalued with flawless balance sheet.
Similar Companies
Market Insights
Weekly Picks

The "Sleeping Giant" Stumbles, Then Wakes Up
Swiped Left by Wall Street: The BMBL Rebound Trade

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For
Recently Updated Narratives
A Quality Compounder Marked Down on Overblown Fears
Etsy Stock: Defending Differentiation in a World of Infinite Marketplaces
Align Technology Stock: Premium Orthodontics in a Cost-Sensitive World
Popular Narratives

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
